Stock PLX PROTALIX BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Protalix BioTherapeutics, Inc.

Equities

PLX

US74365A3095

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
1.21 USD +0.83% Intraday chart for Protalix BioTherapeutics, Inc. +6.14% -32.02%
Mar. 14 Transcript : Protalix BioTherapeutics, Inc., 2023 Earnings Call, Mar 14, 2024
Mar. 14 Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

Number of employees: 208

Sales per Business

USD in Million2022Weight2023Weight Delta
Recombinant Therapeutic Proteins
100.0 %
48 100.0 % 38 100.0 % -19.50%

Sales per region

USD in Million2022Weight2023Weight Delta
Global
56.3 %
22 46.9 % 22 56.3 % -3.33%
United States
26.5 %
12 26.0 % 10 26.5 % -18.08%
Brazil
16.7 %
9 19.8 % 6 16.7 % -32.29%
Italy
0.5 %
3 7.2 % 0 0.5 % -94.50%

Managers

Managers TitleAgeSince
Dror Bashan CEO
 Chief Executive Officer 57 19-06-29
Eyal Rubin DFI
 Director of Finance/CFO 48 19-07-21
Yael Hayon CTO
 Chief Tech/Sci/R&D Officer 41 20-07-04
Yaron Naos COO
 Chief Operating Officer 60 03-12-31
Gina Balderas PRN
 Corporate Officer/Principal - -
Fellous Yael HRO
 Human Resources Officer - 22-07-31

Members of the board

Members of the board TitleAgeSince
Pol Boudes BRD
 Director/Board Member 67 19-11-30
Gwen Melincoff BRD
 Director/Board Member 72 19-11-30
Aharon Schwartz BRD
 Director/Board Member 80 14-10-31
Amos Bar Shalev BRD
 Director/Board Member 71 08-06-30
Eliot Forster CHM
 Chairman 58 23-09-13
Shmuel Ben Zvi BRD
 Director/Board Member 64 22-06-29
Dror Bashan CEO
 Chief Executive Officer 57 19-06-29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 73,052,124 65,915,784 ( 90.23 %) 0 90.23 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
4.494 %
3,283,123 4.494 % 4 M $
Technorov Holdings (1993) Ltd.
3.427 %
2,503,614 3.427 % 3 M $
Hir Investments Ltd.
3.234 %
2,362,783 3.234 % 3 M $
Dror Bashan
3.124 %
2,281,934 3.124 % 3 M $
Marius Nacht
3.024 %
2,208,913 3.024 % 3 M $
STATE STREET CORPORATION
1.131 %
826,581 1.131 % 1 M $
Geode Capital Management LLC
0.9919 %
724,575 0.9919 % 912 965 $
Renaissance Technologies LLC
0.9111 %
665,600 0.9111 % 838 656 $
Eyal Rubin
0.7803 %
570,000 0.7803 % 718 200 $
GSA Capital Partners LLP
0.7450 %
544,238 0.7450 % 685 740 $

Company contact information

Protalix Biotherapeutics, Inc.

2 University Plaza Suite 100

07601, Hackensack

+972 4 902 8100

http://www.protalix.com
address Protalix BioTherapeutics, Inc.(PLX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Protalix BioTherapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.21 USD
Average target price
13 USD
Spread / Average Target
+974.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PROTALIX BIOTHERAPEUTICS, INC. Stock Protalix BioTherapeutics, Inc.
-32.02% 87.66M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+4.09% 43.43B
LONZA GROUP AG Stock Lonza Group AG
+47.81% 41.69B
MODERNA, INC. Stock Moderna, Inc.
+9.45% 41.31B
CELLTRION, INC. Stock Celltrion, Inc.
-10.92% 27.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.32% 25.28B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.87% 18.47B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.70% 12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.28% 12.33B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.78% 11.03B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PLX Stock
  4. Company Protalix BioTherapeutics, Inc.